Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2011 1
2012 3
2013 5
2014 13
2015 20
2016 10
2017 7
2018 8
2019 5
2020 17
2021 23
2022 27
2023 20
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Epidemiology of Renal Cell Carcinoma: 2022 Update.
Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, Kassouf W, Mitchell T, Montironi R, O'Brien T, Panebianco V, Scelo G, Shuch B, van Poppel H, Blosser CD, Psutka SP. Bukavina L, et al. Among authors: psutka sp. Eur Urol. 2022 Nov;82(5):529-542. doi: 10.1016/j.eururo.2022.08.019. Epub 2022 Sep 10. Eur Urol. 2022. PMID: 36100483 Review.
Epidemiology, Screening, and Prevention of Bladder Cancer.
Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, Gupta S, Smith AB, Williams SB, Lotan Y. Lobo N, et al. Among authors: psutka sp. Eur Urol Oncol. 2022 Dec;5(6):628-639. doi: 10.1016/j.euo.2022.10.003. Epub 2022 Nov 1. Eur Urol Oncol. 2022. PMID: 36333236 Review.
EDITORIAL COMMENT.
Nicholson TM, Peters CE, Psutka SP. Nicholson TM, et al. Among authors: psutka sp. Urology. 2022 Apr;162:103-104. doi: 10.1016/j.urology.2021.08.062. Urology. 2022. PMID: 35469603 No abstract available.
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group.
Tan WS, Steinberg G, Witjes JA, Li R, Shariat SF, Roupret M, Babjuk M, Bivalacqua TJ, Psutka SP, Williams SB, Cookson MS, Palou J, Kamat AM. Tan WS, et al. Among authors: psutka sp. Eur Urol Oncol. 2022 Oct;5(5):505-516. doi: 10.1016/j.euo.2022.05.005. Epub 2022 Jun 17. Eur Urol Oncol. 2022. PMID: 35718695 Review.
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
Wu Z, Chen Q, Qu L, Li M, Wang L, Mir MC, Carbonara U, Pandolfo SD, Black PC, Paul AK, Di Lorenzo G, Porpiglia F, Mari A, Necchi A, Rouprêt M, Psutka SP, Autorino R. Wu Z, et al. Among authors: psutka sp. Eur Urol. 2022 Apr;81(4):414-425. doi: 10.1016/j.eururo.2022.01.028. Epub 2022 Jan 31. Eur Urol. 2022. PMID: 35101302 Free article. Review.
Reply by Authors.
Garg H, Psutka SP, Hakimi AA, Kim HL, Mansour AM, Pruthi DK, Liss MA, Wang H, Gaspard CS, Ramamurthy C, Svatek RS, Kaushik D. Garg H, et al. Among authors: psutka sp. J Urol. 2022 Sep;208(3):559. doi: 10.1097/JU.0000000000002829.02. Epub 2022 Sep 1. J Urol. 2022. PMID: 35942785 No abstract available.
Reply by Authors.
Garg H, Psutka SP, Hakimi AA, Kim HL, Mansour AM, Pruthi DK, Liss MA, Wang H, Gaspard CS, Ramamurthy C, Svatek RS, Kaushik D. Garg H, et al. Among authors: psutka sp. J Urol. 2022 Sep;208(3):560. doi: 10.1097/JU.0000000000002829.04. Epub 2022 Sep 1. J Urol. 2022. PMID: 35942787 No abstract available.
Machine Learning in Body Composition Analysis.
Higgins MI, Marquardt JP, Master VA, Fintelmann FJ, Psutka SP. Higgins MI, et al. Among authors: psutka sp. Eur Urol Focus. 2021 Jul;7(4):713-716. doi: 10.1016/j.euf.2021.03.013. Epub 2021 Mar 24. Eur Urol Focus. 2021. PMID: 33771476 Review.
130 results